Successful splenectomy for congenital erythropoietic porphyria (Gunther's disease)

A. K. Shetty, D. Ode, W. K. Galen, R. P. Warrier

Research output: Contribution to journalArticle

Abstract

Congenital erythropoetic porphyria (CEP), also known as Gunther disease is a rare autosomal recessive disorder of porphyrin metabolism caused by deficiency of uroporphyrinogen III synthetase (or cosynthetase). To date no curative therapy is known. The only preventive measure is the absolute avoidance of exposure to sunlight. Other treatments include oral beta-carotene, erythrocyte transfusions, splenectomy, oral administration of adsorbents such as charcoal and cholestyramine, and hydroxyurea administration. None of the above treatments is wholly satisfactory, especially in severely affected patients. We report a 5-year-old child with CEP who presented with a history of pinkish red urine and blistering cutaneous lesions since birth. His clinical course was complicated by severe hemolytic anemia and thrombocytopenia requiring multiple transfusions. He underwent splenectomy with dramatic improvement in his hematological and clinical status. There was significant improvement in the status of his skin disorder 2 years after splenectomy. No transfusion has been necessary since and the hemoglobin level and platelet count has remained normal. Although long-term efficacy remains to be confirmed, we conclude that splenectomy may benefit patients with CEP.

Original languageEnglish
JournalJournal of Investigative Medicine
Volume47
Issue number2
Publication statusPublished - 01-01-1999
Externally publishedYes

Fingerprint

Uroporphyrinogen III Synthetase
Erythropoietic Porphyria
Porphyrias
Splenectomy
Cholestyramine Resin
Hydroxyurea
Charcoal
Porphyrins
beta Carotene
Platelets
Metabolism
Adsorbents
Skin
Hemoglobins
Erythrocyte Transfusion
Sunlight
Hemolytic Anemia
Platelet Count
Thrombocytopenia
Oral Administration

All Science Journal Classification (ASJC) codes

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Shetty, A. K. ; Ode, D. ; Galen, W. K. ; Warrier, R. P. / Successful splenectomy for congenital erythropoietic porphyria (Gunther's disease). In: Journal of Investigative Medicine. 1999 ; Vol. 47, No. 2.
@article{31be43b667cd472697ebb4442d8590a4,
title = "Successful splenectomy for congenital erythropoietic porphyria (Gunther's disease)",
abstract = "Congenital erythropoetic porphyria (CEP), also known as Gunther disease is a rare autosomal recessive disorder of porphyrin metabolism caused by deficiency of uroporphyrinogen III synthetase (or cosynthetase). To date no curative therapy is known. The only preventive measure is the absolute avoidance of exposure to sunlight. Other treatments include oral beta-carotene, erythrocyte transfusions, splenectomy, oral administration of adsorbents such as charcoal and cholestyramine, and hydroxyurea administration. None of the above treatments is wholly satisfactory, especially in severely affected patients. We report a 5-year-old child with CEP who presented with a history of pinkish red urine and blistering cutaneous lesions since birth. His clinical course was complicated by severe hemolytic anemia and thrombocytopenia requiring multiple transfusions. He underwent splenectomy with dramatic improvement in his hematological and clinical status. There was significant improvement in the status of his skin disorder 2 years after splenectomy. No transfusion has been necessary since and the hemoglobin level and platelet count has remained normal. Although long-term efficacy remains to be confirmed, we conclude that splenectomy may benefit patients with CEP.",
author = "Shetty, {A. K.} and D. Ode and Galen, {W. K.} and Warrier, {R. P.}",
year = "1999",
month = "1",
day = "1",
language = "English",
volume = "47",
journal = "Journal of Investigative Medicine",
issn = "1081-5589",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

Successful splenectomy for congenital erythropoietic porphyria (Gunther's disease). / Shetty, A. K.; Ode, D.; Galen, W. K.; Warrier, R. P.

In: Journal of Investigative Medicine, Vol. 47, No. 2, 01.01.1999.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Successful splenectomy for congenital erythropoietic porphyria (Gunther's disease)

AU - Shetty, A. K.

AU - Ode, D.

AU - Galen, W. K.

AU - Warrier, R. P.

PY - 1999/1/1

Y1 - 1999/1/1

N2 - Congenital erythropoetic porphyria (CEP), also known as Gunther disease is a rare autosomal recessive disorder of porphyrin metabolism caused by deficiency of uroporphyrinogen III synthetase (or cosynthetase). To date no curative therapy is known. The only preventive measure is the absolute avoidance of exposure to sunlight. Other treatments include oral beta-carotene, erythrocyte transfusions, splenectomy, oral administration of adsorbents such as charcoal and cholestyramine, and hydroxyurea administration. None of the above treatments is wholly satisfactory, especially in severely affected patients. We report a 5-year-old child with CEP who presented with a history of pinkish red urine and blistering cutaneous lesions since birth. His clinical course was complicated by severe hemolytic anemia and thrombocytopenia requiring multiple transfusions. He underwent splenectomy with dramatic improvement in his hematological and clinical status. There was significant improvement in the status of his skin disorder 2 years after splenectomy. No transfusion has been necessary since and the hemoglobin level and platelet count has remained normal. Although long-term efficacy remains to be confirmed, we conclude that splenectomy may benefit patients with CEP.

AB - Congenital erythropoetic porphyria (CEP), also known as Gunther disease is a rare autosomal recessive disorder of porphyrin metabolism caused by deficiency of uroporphyrinogen III synthetase (or cosynthetase). To date no curative therapy is known. The only preventive measure is the absolute avoidance of exposure to sunlight. Other treatments include oral beta-carotene, erythrocyte transfusions, splenectomy, oral administration of adsorbents such as charcoal and cholestyramine, and hydroxyurea administration. None of the above treatments is wholly satisfactory, especially in severely affected patients. We report a 5-year-old child with CEP who presented with a history of pinkish red urine and blistering cutaneous lesions since birth. His clinical course was complicated by severe hemolytic anemia and thrombocytopenia requiring multiple transfusions. He underwent splenectomy with dramatic improvement in his hematological and clinical status. There was significant improvement in the status of his skin disorder 2 years after splenectomy. No transfusion has been necessary since and the hemoglobin level and platelet count has remained normal. Although long-term efficacy remains to be confirmed, we conclude that splenectomy may benefit patients with CEP.

UR - http://www.scopus.com/inward/record.url?scp=33750125518&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750125518&partnerID=8YFLogxK

M3 - Article

VL - 47

JO - Journal of Investigative Medicine

JF - Journal of Investigative Medicine

SN - 1081-5589

IS - 2

ER -